AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
6 Phases
Drug Approvals
31
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (2760 trials with phase data)• Click on a phase to view related trials
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: AZD6621
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT07192614
- Locations
- 🇰🇷
Research Site, Seoul, South Korea
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Drug: AZD0516
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 177
- Registration Number
- NCT07181161
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
- Conditions
- Ovarian Cancer
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT07167433
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
- Conditions
- Limited Stage Small-Cell Lung Cancer
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT07161388
- Locations
- 🇨🇳
Cancer Hospital of Shandong First Medical University, Jinan, China
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: IV RilvegostomigDrug: SC rilvegostomig + rHuDrug: Recombinant Human Hyaluronidase (rHu)Drug: SC Rilvegostomig
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT07161414
- Prev
- 1
- 2
- 3
- 4
- 5
- 666
- Next
News
Crystalys Therapeutics Emerges with $205M Series A to Advance Gout Treatment Dotinurad
Crystalys Therapeutics launched with $205 million in Series A funding to develop dotinurad, a URAT1 blocker for gout treatment that is already approved in Japan, China, Philippines, and Thailand.
Novartis Launches Direct-to-Patient Platform for Cosentyx with 55% Discount in US
Novartis will launch a direct-to-patient platform on November 1, 2025, offering Cosentyx at a 55% discount off list price to cash-paying patients in the US.
Combination Inhaler Reduces Asthma Attacks in Children by 45% in Landmark Trial
A randomized controlled trial of 360 children aged 5-15 found that a budesonide-formoterol combination inhaler reduced asthma attacks by 45% compared to standard salbutamol treatment.
Factor Bioscience Sues AstraZeneca and Cellectis Over Gene-Editing Patent Infringement
Factor Bioscience filed a patent lawsuit against Cellectis and AstraZeneca in Delaware federal court, alleging infringement of three foundational gene-editing patents related to mRNA TALEN technology.
AstraZeneca Launches Direct-to-Consumer Platform with Up to 70% Drug Discounts Following Trump Administration Pressure
AstraZeneca announced it will offer its diabetes drug Farxiga and asthma drug Airsupra at discounts of up to 70% through a new direct-to-consumer platform launching October 1, 2025.
AIM ImmunoTech Secures Japanese Patent for Ampligen Combination Therapy in Oncology Through 2039
AIM ImmunoTech has secured a Japanese patent covering Ampligen (rintatolimod) in combination with checkpoint inhibitors for cancer treatment, valid until December 20, 2039.
Sanofi Ventures Secures $625 Million to Accelerate Biotech and Digital Health Investments
Sanofi commits an additional $625 million to its corporate venture arm, bringing total assets under management to over $1.4 billion for strategic biotech investments.
Japan Approves OncoGuide OncoScreen Plus CDx System for Breast Cancer Companion Diagnostics
Riken Genesis and Burning Rock Biotech received Japanese regulatory approval for their OncoGuide OncoScreen Plus CDx System as a companion diagnostic for AstraZeneca's capivasertib in breast cancer treatment.
DaltonTx Emerges from Stealth with £4M Seed Funding to Transform Drug Discovery with Adaptive AI Platform
DaltonTx, a UK-based technology company, has completed a £4 million seed financing round to develop adaptive AI-enabled discovery platforms that reshape R&D economics and timelines.
AstraZeneca's Tezspire Receives EU Regulatory Recommendation for Chronic Rhinosinusitis with Nasal Polyps
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of AstraZeneca and Amgen's Tezspire (tezepelumab) for treating chronic rhinosinusitis with nasal polyps in adults.